<DOC>
	<DOCNO>NCT01046461</DOCNO>
	<brief_summary>Cisplatin one emetogenic drug use clinical practice could result poor compliance chemotherapy . The 5-HT3 receptor antagonist prevent vomit acute phase emesis chemotherapy 73 - 92 % cisplatin-treated patient coadministered steroid , appear lack efficacy delay phase emesis . Ramosetron , new 5-HT3 receptor antagonist , show equivalent efficacy tolerability long duration effect granisetron prevent acute vomit patient undergo cisplatin-containing chemotherapy . Acute phase emesis prevent 84.8 % patient receive ramosetron plus dexamethasone , CR rate total phase emesis le 60 % . Aprepitant selective , high-affinity NK1 receptor antagonist . Adding aprepitant 5-HT3 receptor antagonist steroid improve CR rate chemotherapy induce acute emesis also delay emesis 11-14 20 percentage point , respectively . But , information 5-HT3 receptor antagonist best partner aprepitant . Therefore , initiated prospective , open-label , phase II study ass efficacy tolerability combination ramosetron , aprepitant dexamethasone ( RAD ) prevention cisplatin base CINV chemotherapy-naïve patient solid cancer</brief_summary>
	<brief_title>Ramosetron , Aprepitant Dexamethasone ( RAD ) Solid Cancer</brief_title>
	<detailed_description>Cisplatin one emetogenic drug use clinical practice could result poor compliance chemotherapy . The 5-HT3 receptor antagonist prevent vomit acute phase emesis chemotherapy 73 - 92 % cisplatin-treated patient coadministered steroid , appear lack efficacy delay phase emesis . Ramosetron , new 5-HT3 receptor antagonist , show equivalent efficacy tolerability long duration effect granisetron prevent acute vomit patient undergo cisplatin-containing chemotherapy . Acute phase emesis prevent 84.8 % patient receive ramosetron plus dexamethasone , CR rate total phase emesis le 60 % .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>18 75 year , sex ECOG performance status 02 Histologically proven solid cancer , chemotherapynaïve patient Planed receive cisplatin ( ≥ 50mg/m2 ) base , single day chemotherapy , No nausea vomit within 72 hour prior chemotherapy Serum Cr &lt; 2.5 mg/dl , calculate CCr ≥ 50 ml/min Serum total bilirubin &lt; 2 mg/dl , AST/ALT &lt; 3 time upper normal limit , ALP &lt; 5 time upper normal limit Absolute neutrophil count ≥ 1,500/μL , platelet ≥ 100,000/μL Expected life duration ≥ 3 month Patients must sign informed consent indicate aware investigational nature study keep policy hospital Patients active infection , severe heart disease , uncontrollable hypertension diabetes mellitus , active gastric duodenal ulcer , pregnancy breastfeeding Patients take steroid , antiemetic , pimozide , terfenadine , astemizole , cisapride , rifampin , carbamazepine , phenytoin , ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir nelfinavir treatment diseases Patients take medicine , could affect study result , within 1 week chemotherapy ( take antiemetic within 48 hour chemotherapy ) . Prior begin chemotherapy , singleagent benzodiazepine hypnotic allow , ca n't receive day 16 1st chemotherapy cycle . Patients symptomatic brain metastasis Patients GI obstruction disease could provoke nausea vomit Patients receive RT brain , abdomen pelvis within 2 week chemotherapy Patients understand inform consent express his/her condition Patients swallow drug Patients know allergy severe side effect study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Ramosetron</keyword>
	<keyword>aprepitant</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>antiemetic</keyword>
	<keyword>cisplatin</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>high dose cisplatin</keyword>
</DOC>